Using oral hypoglycemic agents to treat diabetes mellitus in cats

Veterinary Medicine

Volumn 93, Issue 8, 1998, Pages 736-742

  Garcia, Jennifer L ^a,b   Bruyette, David S ^a  

^a USA   (United States)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0345930913     PISSN: 87507943     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Feldman, E.C. et al: Diabetes mellitus. Canine and Feline Endocrinology and Reproduction, 2nd Ed. W.B. Saunders, Philadelphia, Pa., 1996; pp 339-391.
2. Nelson, R.W.: Diabetes mellitus. Textbook of Veterinary Internal Medicine, 4th Ed. (S.J. Ettinger; E.C. Feldman, eds.). W.B. Saunders, Philadelphia, Pa., 1995; pp 1510-1537.
3. Groop, L.C.: Sulfonylureas in NIDDM. Diabetes Care 75:737-748; 1992.
4. Melander, A.: Clinical pharmacology of sulfonylureas. Metabolism 28:12-16; 1987.
5. Tal, A.: Oral hypoglycemic agents in the treatment of type II diabetes. Am. Fam. Physician 45:1089-1095; 1993.
6. Tan, G.H. et al: Concise review for primary care physicians. Mayo Clin. Proc. 77:763-768; 1996.
7. Nelson, R.W. et al: Effect of an orally administered sulfonylurea, glipizide, for the treatment of diabetes mellitus in cats. JAVMA 203:821-827; 1993.
8. Ford, S.L.: NIDDM in the cat: Treatment with oral hypoglycemic medication, glipizide. Vet. Clin. North Am. 25:599-614; 1995.
9. Feldman, E.C. et al: Intensive 50-week evaluation of glipizide administration in 50 cats with previously untreated diabetes mellitus. JAVMA 210:772-777; 1997.
10. Nelson, R.W. et al: Treatment of feline diabetes mellitus with the oral sulfonylurea, glipizide. Kirk's Current Veterinary Therapy XII Small Animal Practice (J.D. Bonagura, ed.). W.B. Saunders, Philadelphia, Pa., 1995; pp 401-403.
11. Heine, R.J.: Role of sulfonylureas in NIDDM: Part II-"The cons." Horm. Metab. Res. 28:522-526; 1996.
12. Bressler, R. et al: Pharmacological regulation of blood glucose levels in NIDDM. Arch. Intern. Med. 157:836-846; 1997.
13. Harrower, A.D.B.: Pharmocokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin. Pharmacokinet. 2:111-118; 1996.
14. Bailey, C.J. et al: Traditional plant medicines as treatments for diabetes. Diabetes Care 12:553-563; 1989.
15. Melchior, W.R. et al: Metformin: An antihyperglycemic agent for the treatment of type II diabetes. Ann. Pharmacol. 30:158-163; 1996.
16. Goo, A.K.Y. et al: A new treatment option for NIDDM. J. Fam. Pract. 42:612-618; 1996.
17. Bailey, C.J. et al: Metformin. N. Engl. J. Med. 334:574-579; 1996.
18. Wollen, N. et al: Inhibition of hepatic gluconeogenesis by metformin. Biochem. Pharmacol. 37:4353-4358; 1988.
19. Bailey, C.J.: Biguanides and NIDDM. Diabetes Care 15:755-771; 1992.
20. Stumvoll, M. et al: Metabolic effects of metformin in NIDDM. N. Engl. J. Med. 333:550-554; 1995.
21. Martin, A.E. et al: Acarbose: An α-glucosidase inhibitor. Am. J. Health-Syst. Pharmacol. 53:2277-2290; 1996.
22. Coniff, R.F. et al: A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 18:928-932; 1995.
23. Chiasson, J.L. et al: The efficacy of acarbose in the treatment of patients with NIDDM. Ann. Intern. Med. 121:928-935; 1994.
24. Bayraktar, M. et al: A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes Care 19:252-254; 1996.
25. Greco, D.: Treatment of NIDDM with oral hypoglycemic agents. Proc. ACVIM, ACVIM, Blacksburg, Va., 1997; pp 252-255.
26. Kuehnle, H. F.: New therapeutic agents for the treatment of NIDDM. Exp. Clin. Endocrinol. Diabetes 104:93-101; 1996.
27. Speerhas, R.A. et al: Troglitazone: A new antihyperglycemic agent. Cleve. Clin. J. Med. 64:238-240; 1997.
28. Nolan, J.J. et al: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331:1188-1193; 1994.
29. Saltiel, A.R. et al: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669; 1996.
30. Kumar, S. et al: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39:701-709; 1996.